Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : U.S. Department of Health and Human Services
Deal Size : $129.0 million
Deal Type : Funding
Kindeva Secures $129M SNS Contract for Nerve Agent Antidote
Details : The funding aims to advance the the manufacturing of DuoDote (atropine and pralidoxime chloride). It is indicated for the treatment of poisoning by organophosphorus nerve agents.
Product Name : Duodote
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2025
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : U.S. Department of Health and Human Services
Deal Size : $129.0 million
Deal Type : Funding
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved
Sponsor : ASPR
Deal Size : $9.9 million
Deal Type : Agreement
Details : Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent anti...
Product Name : DuoDote
Product Type : Small molecule
Upfront Cash : Undisclosed
November 14, 2023
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved
Sponsor : ASPR
Deal Size : $9.9 million
Deal Type : Agreement